z-logo
open-access-imgOpen Access
Gram Negative Extended Spectrum Beta-Lactamase Producing Bacteria Prevalence in Jouf Region Tertiary Care Hospital, Saudi Arabia
Author(s) -
Javid Iqbal Rather,
Zahoor Mohi ud din,
Farkhanda N. Syed,
Mir Haris,
Mudasar Nabi,
Ambreena Farooq,
Bilal Ahmad Tantry,
Abdul Hafeez Muhammed,
Shaik Rahiman
Publication year - 2021
Publication title -
journal of pure and applied microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.149
H-Index - 16
eISSN - 2581-690X
pISSN - 0973-7510
DOI - 10.22207/jpam.15.1.39
Subject(s) - sputum , klebsiella pneumoniae , antibiotics , medicine , microbiology and biotechnology , klebsiella pneumonia , antimicrobial , antibiotic resistance , biology , pseudomonas aeruginosa , tuberculosis , bacteria , escherichia coli , biochemistry , genetics , pathology , gene
Extended Spectrum beta lactamase producing pathogens are reported in many clinical samples and pose an emerging threat health. To find the prevalence of ESBL producing Enterobactriacea pathogens isolated from inpatients (Medical and Surgical Wards; Hospital stay > 72 h) admitted to Prince, Mutib, Hospital Sakaka, Jouf. A total of 1043 Enterobactriacea were isolated during April 2015 to October 2016 study period. Vitek -2 compact (biomeriux Leon, France) was used for identification and antimicrobial sensitivity (AST) test. A Total of 115/1043 (11.02%) ESBL producing pathogens were isolated from urine 15.07% (n=242), sputum 13.6 % (n=220), wound 10.8% (n=287) and blood 5.4 % (n=294). Klebsiella pneumonia is most dominant followed by E coli and Proteus miribilis. Cephamycins and carbapenems were found most effective (100% sensitivity) against the pathogens isolated. The aminoglycosides, beta lactams and Fluroquinolnes class of antibiotics, microorganisms have gained the resistance of 20%, 22.7%, 40-70% respectively. The infection control measures should be taken seriously and making of effective use of antibiotics is need of hour.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here